Gene electrotransfer to skin; review of existing literature and clinical perspectives

Current Gene Therapy

Volumn 10, Issue 4, 2010, Pages 287-299

  Gothelf, Anita ^a   Gehl, Julie ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Electroporation; Gene electrotransfer; Gene therapy; Non viral; Review; Skin

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; AMEP PROTEIN; BETA GALACTOSIDASE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DNA VACCINE; ERYTHROPOIETIN; GREEN FLUORESCENT PROTEIN; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 12; KERATINOCYTE GROWTH FACTOR; LUCIFERASE; MALARIA VACCINE; METARGIDIN; OVALBUMIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; SECRETED EMBRYONIC ALKALINE PHOSPHATASE; SMALLPOX VACCINE; SURVIVIN; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIGEN PRESENTING CELL; CANCER GENE THERAPY; CANCER IMMUNIZATION; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOSTASIS; ELECTRIC POTENTIAL; ELECTRODE; ELECTROPORATION; EX VIVO GENE TRANSFER; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENETIC TRANSFECTION; HISTOLOGY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; KERATINOCYTE; MELANOMA; MUTAGENESIS; MYCOSIS FUNGOIDES; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARACRINE SIGNALING; PHENYLKETONURIA; PLASMID; PROMOTER REGION; REPORTER GENE; REVIEW; SOFT TISSUE SARCOMA; TRANSGENE; WOUND; WOUND HEALING;

ANIMALS; ELECTRODES; ELECTROPORATION; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MICE; MUSCLE, SKELETAL; NEOPLASMS; PLASMIDS; PROMOTER REGIONS, GENETIC; SKIN; SKIN DISEASES; SKIN PHYSIOLOGICAL PHENOMENA; VACCINES, DNA; WOUND HEALING;

ANIMALIA;

EID: 77958028255     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652310791823443     Document Type: Review

References (123)

1. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of genetherapy with an adeno-associated virus (AAV) borne GAD gene forParkinson's disease: an open label, phase I trial. Lancet 2007; 369(9579): 2097-105.
2. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase Isafety trial of hAADC gene therapy for Parkinson disease. Neurology 2008; 70(21): 1980-3.
3. Chevez-Barrios P, Chintagumpala M, Mieler W, et al. Response ofretinoblastoma with vitreous tumor seeding to adenovirus-mediateddelivery of thymidine kinase followed by ganciclovir. J Clin Oncol 2005; 23(31): 7927-35.
4. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vectordeliveredpigment epithelium-derived factor for neovascular agerelatedmacular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17(2): 167-76.
5. Harvey BG, Leopold PL, Hackett NR, et al. Airway epithelialCFTR mRNA expression in cystic fibrosis patients after repetitiveadministration of a recombinant adenovirus. J Clin Invest 1999; 104(9): 1245-55.
6. Hyde SC, Southern KW, Gileadi U, et al. Repeat administration ofDNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000; 7(13): 1156-65.
7. Moss RB, Rodman D, Spencer LT, et al. Repeated adenoassociatedvirus serotype 2 aerosol-mediated cystic fibrosis transmembraneregulator gene transfer to the lungs of patients with cysticfibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125(2): 509-21.
8. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardialplasmid vascular endothelial growth factor-A165 gene therapy inpatients with stable severe angina pectoris A randomized doubleblindplacebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005; 45(7): 982-8.
9. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapyin patients with nonrevascularizable ischemic heart disease: a phase2 randomized, controlled trial of Ad VEGF(121) (Ad VEGF121)versus maximum medical treatment. Gene Ther 2006; 13(21): 1503-11.
10. Makinen K, Manninen H, Hedman M, et al. Increased vascularitydetected by digital subtraction angiography after VEGF gene transferto human lower limb artery: a randomized, placebo-controlled,double-blinded phase II study. Mol Ther 2002; 6(1): 127-33.
11. Rajagopalan S, Mohler ER, III, Lederman RJ, et al. Regional angiogenesiswith vascular endothelial growth factor in peripheral arterialdisease: a phase II randomized, double-blind, controlled studyof adenoviral delivery of vascular endothelial growth factor 121 inpatients with disabling intermittent claudication. Circulation 2003; 108(16): 1933-8.
12. Romero NB, Braun S, Benveniste O, et al. Phase I study of dystrophinplasmid-based gene therapy in Duchenne/Becker musculardystrophy. Hum Gene Ther 2004; 15(11): 1065-76.
13. Mavilio F, Pellegrini G, Ferrari S, et al. Correction of junctionalepidermolysis bullosa by transplantation of genetically modifiedepidermal stem cells. Nat Med 2006; 12(12): 1397-402.
14. + Tlymphocytesin HIV-infected patients. J Gene Med 2005; 7(5): 552-64.
15. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humansusing a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103(46): 17372-7.
16. Roth DA, Tawa NE, Jr., O'Brien JM, Treco DA, Selden RF. Nonviraltransfer of the gene encoding coagulation factor VIII in patientswith severe hemophilia A. N Engl J Med 2001; 344(23): 1735-42.
17. Powell JS, Ragni MV, White GC, et al. Phase 1 trial of FVIII genetransfer for severe hemophilia A using a retroviral construct administeredby peripheral intravenous infusion. Blood 2003; 102(6): 2038-45.
18. Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, et al. Gene therapyof human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288(5466): 669-72.
19. Hacein-Bey-Abina S, Le DF, Carlier F, et al. Sustained correctionof X-linked severe combined immunodeficiency by ex vivo genetherapy. N Engl J Med 2002; 346(16): 1185-93.
20. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stemcell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296(5577): 2410-3.
21. Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitutionof immunity in ADA-SCID by stem cell gene therapy followingcessation of PEG-ADA and use of mild preconditioning. Mol Ther 2006; 14(4): 505-13.
22. Brigham KL, Lane KB, Meyrick B, et al. Transfection of nasalmucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther 2000; 11(7): 1023-32.
23. Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscularinjection of a recombinant adeno-associated virus serotype2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006; 17(12): 1177-86.
24. Rainov NG. A phase III clinical evaluation of herpes simplex virustype 1 thymidine kinase and ganciclovir gene therapy as an adjuvantto surgical resection and radiation in adults with previouslyuntreated glioblastoma multiforme. Hum Gene Ther 2000; 11(17): 2389-401.
25. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of Onco VEXGM-CSF, a second-generation oncolytic herpes simplex virusexpressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12(22): 6737-47.
26. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regressionin patients after transfer of genetically engineered lymphocytes. Science 2006; 314(5796): 126-9.
27. Small EJ, Carducci MA, Burke JM, et al. A phase I trial of intravenousCG7870, a replication-selective, prostate-specific antigentargetedoncolytic adenovirus, for the treatment of hormonerefractory,metastatic prostate cancer. Mol Ther 2006; 14(1): 107-17.
28. Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26(36): 5896-903.
29. Alexander BL, Ali RR, Alton EW, et al. Progress and prospects:gene therapy clinical trials (part 1). Gene Ther 2007; 14(20): 1439-47.
30. Hacein-Bey-Abina S, von KC, Schmidt M, et al. LMO2-associatedclonal T cell proliferation in two patients after gene therapy forSCID-X1. Science 2003; 302(5644): 415-9.
31. Mehier-Humbert S, Guy RH. Physical methods for gene transfer:improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev 2005; 57(5): 733-53.
32. Pathak A, Patnaik S, Gupta KC. Recent trends in non-viral vectormediatedgene delivery. Biotechnol J 2009; 4(11): 1559-72.
33. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation-enhanced nonviral gene transfer for the prevention or treatmentof immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006; 6(2): 243-73.
34. Wolff JA, Budker V. The mechanism of naked DNA uptake andexpression. Adv Genet 2005; 54: 3-20.
35. Jensen TG. Gene transfer into human epidermis as an experimentalmodel for somatic gene therapy. Dan Med Bull 2004; 51(2): 155-66.
36. Stein U, Walther W, Stege A, et al. Complete in vivo reversal ofthe multidrug resistance phenotype by jet-injection of anti-MDR1short hairpin RNA-encoding plasmid DNA. Mol Ther 2008; 16(1): 178-86.
37. Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid deliveryby in vivo electroporation for the successful treatment of establishedsubcutaneous B16.F10 melanoma. Mol Ther 2002; 5(6): 668-75.
38. McCray AN, Ugen KE, Heller R. Enhancement of anti-melanomaactivity of a plasmid expressing HIV-1 Vpr delivered through invivo electroporation. Cancer Biol Ther 2007; 6(8): 1269-75.
39. Hojman P, Gissel H, Gehl J. Sensitive and precise regulation ofhaemoglobin after gene transfer of erythropoietin to muscle tissueusing electroporation. Gene Ther 2007; 14(12): 950-9.
40. Trochon-Joseph V, Martel-Renoir D, Mir LM, et al. Evidence ofantiangiogenic and antimetastatic activities of the recombinant disintegrindomain of metargidin. Cancer Res 2004; 64(6): 2062-9.
41. Gothelf A, Hojman P, Gehl J. Therapeutic levels of erythropoietin(EPO) achieved after gene electrotransfer to skin in mice. Gene Ther 2010; doi: 10.1038/gt.2010.46.
42. Pavlin D, Cemazar M, Kamensek U, et al. Local and systemicantitumor effect of intratumoral and peritumoral IL-12 electrogenetherapy on murine sarcoma. Cancer Biol Ther 2009; 8(22): 2114-22.
43. Foldvari M, Babiuk S, Badea I. DNA delivery for vaccination andtherapeutics through the skin. Curr Drug Deliv 2006; 3(1): 17-28.
44. Kanitakis J. Anatomy, histology and immunohistochemistry ofnormal human skin. Eur J Dermatol 2002; 12(4): 390-9.
45. Katz AB, Taichman LB. Epidermis as a secretory tissue: an in vitrotissue model to study keratinocyte secretion. J Invest Dermatol 1994; 102(1): 55-60.
46. Titomirov AV, Sukharev S, Kistanova E. In vivo electroporationand stable transformation of skin cells of newborn mice by plasmidDNA. Biochim Biophys Acta 1991; 1088(1): 131-4.
47. Medi BM, Singh J. Skin targeted DNA vaccine delivery usingelectroporation in rabbits II. Safety. Int J Pharm 2006; 308(1-2): 61-8.
48. Favard C, Dean DS, Rols MP. Electrotransfer as a non viral methodof gene delivery. Curr Gene Ther 2007; 7(1): 67-77.
49. Heller LC, Jaroszeski MJ, Coppola D, Heller R. Comparison ofelectrically mediated and liposome-complexed plasmid DNA deliveryto the skin. Genet Vaccines Ther 2008; 6: 16.
50. Hojman P, Gissel H, Andre F, et al. Physiological effects of highand low voltage pulse combinations for gene electrotransfer inmuscle. Hum Gene Ther 2008.
51. Mir LM, Bureau MF, Rangara R, Schwartz B, Scherman D. Longterm,high level in vivo gene expression after electric pulsemediatedgene transfer into skeletal muscle. C R Acad Sci III1998; 321(11): 893-9.
52. Muramatsu T, Arakawa S, Fukazawa K, et al. In vivo gene electroporationin skeletal muscle with special reference to the duration ofgene expression. Int J Mol Med 2001; 7(1): 37-42.
53. Hojman P, Eriksen J, Gehl J. In Vivo Imaging of Far-red Fluorescent Proteins after DNA Electrotransfer to Muscle Tissue. Biol Proced Online 2009, [Epub ahead of Print].
54. Blair-Parks K, Weston BC, Dean DA. High-level gene transfer tothe cornea using electroporation. J Gene Med 2002; 4(1): 92-100.
55. Dean DA, hado-Aranda D, Blair-Parks K, Yeldandi AV, Young JL. Electroporation as a method for high-level nonviral gene transfer tothe lung. Gene Ther 2003; 10(18): 1608-15.
56. Heller R, Jaroszeski M, Atkin A, et al. In vivo gene electroinjectionand expression in rat liver. FEBS Lett 1996; 389(3): 225-8.
57. Tsujie M, Isaka Y, Nakamura H, Imai E, Hori M. Electroporationmediatedgene transfer that targets glomeruli. J Am Soc Nephrol 2001; 12(5): 949-54.
58. Iwashita H, Yoshida M, Nishi T, Otani M, Ueda S. In vivo transferof a neuronal nitric oxide synthase expression vector into the ratbladder by electroporation. BJU Int 2004; 93(7): 1098-103.
59. Widlak W, Scieglinska D, Vydra N, Malusecka E, Krawczyk Z. Invivo electroporation of the testis versus transgenic mice model infunctional studies of spermatocyte-specific hst70 gene promoter: Acomparative study. Mol Reprod Dev 2003; 65(4): 382-8.
60. Rols MP, Delteil C, Golzio M, et al. In vivo electrically mediatedprotein and gene transfer in murine melanoma. Nat Biotechnol 1998; 16(2): 168-71.
61. Kishida T, Asada H, Satoh E, et al. In vivo electroporationmediatedtransfer of interleukin-12 and interleukin-18 genes inducessignificant antitumor effects against melanoma in mice. Gene Ther 2001; 8(16): 1234-40.
62. Cemazar M, Sersa G, Wilson J, et al. Effective gene transfer tosolid tumors using different nonviral gene delivery techniques:electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther 2002; 9(4): 399-406.
63. Pavselj N, Preat V. DNA electrotransfer into the skin using a combinationof one high-and one low-voltage pulse. J Control Release 2005; 106(3): 407-15.
64. Heller LC, Jaroszeski MJ, Coppola D, et al. Optimization of cutaneouselectrically mediated plasmid DNA delivery using novelelectrode. Gene Ther 2007; 14(3): 275-80.
65. Gothelf A, Eriksen J, Hojman P, Gehl J. Duration and level oftransgene expression after gene electrotransfer to skin in mice. Gene Ther 2010; doi: 10.1038/gt.2010.35.
66. Maruyama H, Miyazaki J, Gejyo F. Epidermis-targeted gene transferusing in vivo electroporation. Methods Mol Biol 2005; 289: 431-6.
67. Marti GP, Mohebi P, Liu L, et al. KGF-1 for wound healing inanimal models. Methods Mol Biol 2008; 423: 383-91.
68. Medi BM, Singh J. Delivery of DNA into skin via electroporation. Methods Mol Biol 2008; 423: 225-32.
69. Roos AK, King A, Pisa P. DNA vaccination for prostate cancer. Methods Mol Biol 2008; 423: 463-72.
70. Pavselj N, Preat V, Miklavcic D. A numerical model of skin electropermeabilizationbased on in vivo experiments. Ann Biomed Eng 2007; 35(12): 2138-44.
71. Mazeres S, Sel D, Golzio M, et al. Non invasive contact electrodesfor in vivo localized cutaneous electropulsation and associated drugand nucleic acid delivery. J Control Release 2009; 134(2): 125-31.
72. Sato M, Tanigawa M, Kikuchi N. Nonviral gene transfer to surfaceskin of mid-gestational murine embryos by intraamniotic injectionand subsequent electroporation. Mol Reprod Dev 2004; 69(3): 268-77.
73. Zhang L, Li L, Hoffmann GA, Hoffman RM. Depth-targeted efficientgene delivery and expression in the skin by pulsed electricfields: an approach to gene therapy of skin aging and other diseases. Biochem Biophys Res Commun 1996; 220(3): 633-6.
74. Zhang L, Nolan E, Kreitschitz S, Rabussay DP. Enhanced deliveryof naked DNA to the skin by non-invasive in vivo electroporation. Biochim Biophys Acta 2002; 1572(1): 1-9.
75. Thanaketpaisarn O, Nishikawa M, Yamashita F, Hashida M. Tissue-specific characteristics of in vivo electric gene: transfer by tissueand intravenous injection of plasmid DNA. Pharm Res 2005; 22(6): 883-91.
76. Medi BM, Hoselton S, Marepalli RB, Singh J. Skin targeted DNAvaccine delivery using electroporation in rabbits. I: efficacy. Int J Pharm 2005; 294(1-2): 53-63.
77. Maruyama H, Ataka K, Higuchi N, et al. Skin-targeted gene transferusing in vivo electroporation. Gene Ther 2001; 8(23): 1808-12.
78. Pedron-Mazoyer S, Plouet J, Hellaudais L, Teissie J, Golzio M. New anti angiogenesis developments through electroimmunization:optimization by in vivo optical imaging of intradermalelectro gene transfer. Biochim Biophys Acta 2007; 1770(1): 137-42.
79. Chesnoy S, Huang L. Enhanced cutaneous gene delivery followingintradermal injection of naked DNA in a high ionic strength solution. Mol Ther 2002; 5(1): 57-62.
80. Glasspool-Malone J, Somiari S, Drabick JJ, Malone RW. Efficientnonviral cutaneous transfection. Mol Ther 2000; 2(2): 140-6.
81. Drabick JJ, Glasspool-Malone J, King A, Malone RW. Cutaneoustransfection and immune responses to intradermal nucleic acid vaccinationare significantly enhanced by in vivo electropermeabilization. Mol Ther 2001; 3(2): 249-55.
82. Babiuk S, Baca-Estrada ME, Foldvari M, et al. Needle-free topicalelectroporation improves gene expression from plasmids administeredin porcine skin. Mol Ther 2003; 8(6): 992-8.
83. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R,Weiner DB. Intradermal/subcutaneous immunization by electroporationimproves plasmid vaccine delivery and potency in pigs andrhesus macaques. Vaccine 2008; 26(3): 440-8.
84. Dujardin N, Van Der SP, Preat V. Topical gene transfer into ratskin using electroporation. Pharm Res 2001; 18(1): 61-6.
85. Gao Z, Wu X, Song N, Cao Y, Liu W. Electroporation-mediatedplasmid gene transfer in rat incisional wound. J Dermatol Sci 2007; 47(2): 161-4.
86. Heller R, Cruz Y, Heller LC, Gilbert RA, Jaroszeski MJ. Electrically Mediated Delivery of Plasmid DNA to the Skin Using a Multi Electrode Array. Hum Gene Ther 2009.
87. Heller R, Schultz J, Lucas ML, et al. Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation. DNA Cell Biol 2001; 20(1): 21-6.
88. Lucas ML, Jaroszeski MJ, Gilbert R, Heller R. In vivo electroporationusing an exponentially enhanced pulse: a new waveform. DNACell Biol 2001; 20(3): 183-8.
89. Byrnes CK, Malone RW, Akhter N, et al. Electroporation enhancestransfection efficiency in murine cutaneous wounds. Wound Repair Regen 2004; 12(4): 397-403.
90. Lee PY, Chesnoy S, Huang L. Electroporatic delivery of TGFbeta1gene works synergistically with electric therapy to enhancediabetic wound healing in db/db mice. J Invest Dermatol 2004; 123(4): 791-8.
91. Roos AK, Moreno S, Leder C, et al. Enhancement of cellular immuneresponse to a prostate cancer DNA vaccine by intradermalelectroporation. Mol Ther 2006; 13(2): 320-7.
92. +) onin vivo gene transfer by electroporation. Acta Pharmacol Sin 2006; 27(3): 307-10.
93. Vandermeulen G, Staes E, Vanderhaeghen ML, et al. Optimisationof intradermal DNA electrotransfer for immunisation. J Control Release 2007; 124(1-2): 81-7.
94. Kang JH, Toita R, Niidome T, Katayama Y. Effective delivery ofDNA into tumor cells and tissues by electroporation of polymer-DNA complex. Cancer Lett 2008; 265(2): 281-8.
95. Liu L, Marti GP, Wei X, et al. Age-dependent impairment of HIF-1alpha expression in diabetic mice: Correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis,and circulating angiogenic cells. J Cell Physiol 2008.
96. Roos AK, Eriksson F, Timmons JA, et al. Skin electroporation:effects on transgene expression, DNA persistence and local tissueenvironment. PLoS ONE 2009; 4(9): e7226.
97. Roos AK, Eriksson F, Walters DC, Pisa P, King AD. Optimizationof Skin Electroporation in Mice to Increase Tolerability of DNAVaccine Delivery to Patients. Mol Ther 2009; 17(9): 1637-42.
98. Vandermeulen G, Richiardi H, Escriou V, et al. Skin-specific promotersfor genetic immunisation by DNA electroporation. Vaccine 2009; 27(32): 4272-7.
99. Vandermeulen G, Daugimont L, Richiardi H, et al. Effect of tapestripping and adjuvants on immune response after intradermalDNA electroporation. Pharm Res 2009; 26(7): 1745-51.
100. Gothelf A, Mahmood F, Dagnaes-Hansen F, Gehl J. Importance ofelectrodes in gene electrotransfer to porcine skin; evaluated by efficacyof transgene expression and electric field calculation. Submittedfor publication 2010.
101. Lin MP, Marti GP, Dieb R, et al. Delivery of plasmid DNA expressionvector for keratinocyte growth factor-1 using electroporationto improve cutaneous wound healing in a septic rat model. Wound Repair Regen 2006; 14(5): 618-24.
102. Andre FM, Gehl J, Sersa G, et al. Efficiency of High-and Low-Voltage Pulse Combinations for Gene Electrotransfer in Muscle,Liver, Tumor, and Skin. Human Gene Therapy 2008; 19(11): 1261-72.
103. Marti G, Ferguson M, Wang J, et al. Electroporative transfectionwith KGF-1 DNA improves wound healing in a diabetic mousemodel. Gene Ther 2004; 11(24): 1780-5.
104. Ferraro B, Cruz YL, Coppola D, Heller R. Intradermal delivery ofplasmid VEGF(165) by electroporation promotes wound healing. Mol Ther 2009; 17(4): 651-7.
105. Zhang L, Widera G, Rabussay D. Enhancement of the effectivenessof electroporation-augmented cutaneous DNA vaccination by aparticulate adjuvant. Bioelectrochemistry 2004; 63(1-2): 369-73.
106. Martinon F, Kaldma K, Sikut R, et al. Persistent Immune Responses Induced by a Human Immunodeficiency Virus DNA Vaccine Delivered in Association with Electroporation in the Skin ofNonhuman Primates. Hum Gene Ther 2009; 20(11): 1291-307.
107. Dobano C, Widera G, Rabussay D, Doolan DL. Enhancement ofantibody and cellular immune responses to malaria DNA vaccinesby in vivo electroporation. Vaccine 2007; 25(36): 6635-45.
108. Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNAvaccine delivered by novel skin electroporation device protectsmice against intranasal poxvirus challenge. Vaccine 2007; 25(10): 1814-23.
109. Brave A, Hallengard D, Gudmundsdotter L, et al. Late administrationof plasmid DNA by intradermal electroporation efficientlyboosts DNA-primed T and B cell responses to carcinoembryonicantigen. Vaccine 2009; 27(28): 3692-6.
110. Lladser A, Ljungberg K, Tufvesson H, et al. Intradermal DNAelectroporation induces survivin-specific CTLs, suppresses angiogenesisand confers protection against mouse melanoma. Cancer Immunol Immunother 2009; 59(1): 81-92.
111. Gareau DS, Bargo PR, Horton WA, Jacques SL. Confocal fluorescencespectroscopy of subcutaneous cartilage expressing greenfluorescent protein versus cutaneous collagen autofluorescence. JBiomed Opt 2004; 9(2): 254-8.
112. Shcherbo D, Merzlyak EM, Chepurnykh TV, et al. Bright far-redfluorescent protein for whole-body imaging. Nat Methods 2007; 4(9): 741-6.
113. Odgren PR, MacKay CA, Mason-Savas A, et al. False-positivebeta-galactosidase staining in osteoclasts by endogenous enzyme:studies in neonatal and month-old wild-type mice. Connect Tissue Res 2006; 47(4): 229-34.
114. Sanchez-Ramos J, Song S, Dailey M, et al. The X-gal caution inneural transplantation studies. Cell Transplant 2000; 9(5): 657-67.
115. Tuting T, Storkus WJ, Falo LD, Jr. DNA immunization targetingthe skin: molecular control of adaptive immunity. J Invest Dermatol 1998; 111(2): 183-8.
116. Liu MA. DNA vaccines: a review. J Intern Med 2003; 253(4): 402-10.
117. Peng B, Zhao Y, Xu L, Xu Y. Electric pulses applied prior to intramuscularDNA vaccination greatly improve the vaccine immunogenicity. Vaccine 2007; 25(11): 2064-73.
118. Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional andtherapeutic biology of survivin. Cancer Lett 2006; 244(2): 164-71.
119. Menck CF, Armelini MG, Lima-Bessa KM. On the search for skingene therapy strategies of xeroderma pigmentosum disease. Curr Gene Ther 2007; 7(3): 163-74.
120. Long HA, McMillan JR, Qiao H, Akiyama M, Shimizu H. Currentadvances in gene therapy for the treatment of genodermatoses. Curr Gene Ther 2009; 9(6): 487-94.
121. Peycheva E, Daskalov I, Tsoneva I. Electrochemotherapy of Mycosisfungoides by interferon-alpha. Bioelectrochemistry 2007; 70(2): 283-6.
122. Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic andpharmacodynamic studies of a human serum albumin-interferonalphafusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303(2): 540-8.
123. Christensen R, Kolvraa S, Blaese RM, Jensen TG. Development ofa skin-based metabolic sink for phenylalanine by overexpression ofphenylalanine hydroxylase and GTP cyclohydrolase in primaryhuman keratinocytes. Gene Ther 2000; 7(23): 1971-8.